Jayakrishna Ambati, MD, discusses phase 2 K8 findings in geographic atrophy, inflammasome targeting and K8 dosing and delivery.

October spotlights eye-care breakthroughs: phase 3 gene therapies, sustained delivery, and AAO trial data, plus 3 FDA clearances shaping retina, cataract, and TED care.

Veeral S. Sheth, MD, MBA, FACS, FASRS, discusses the evidence behind the new labeling requirement and how it aligns with the AAO/NANOS consensus statement.

Josef Huemer, MD, discusses retinal changes linked to atrial fibrillation and what they mean for eye care clinicians.

The first-in-human study of the GalNAc-conjugated siRNA joins a fast-moving Stargardt pipeline as the FDA weighs the first potential approval for the disease.

Katherine Talcott, MD, discusses phase 2 VERONA findings on the vorolanib intravitreal insert in previously treated DME

VeonGen aligns with FDA on phase 3 design for VG801, a dual-AAV Stargardt gene therapy, after uncontrolled phase 1/2 BCVA gains.

Jayakrishna Ambati, MD, discusses phase 2 K8 results in GA, its inflammasome mechanism, and dosing designed for convenience.